Study Evaluating Effexor XR for Major Depression.

Wyeth

Status and phase: Completed; Phase 3

Conditions: Depression

Treatments: Drug: Effexor XR; Drug: Milnacipran

Study type: Interventional

Funder types: Industry

Identifiers

NCT00225511

0600B1-816

Details and patient eligibility

About

Study Evaluating Effexor XR for Major Depression.

Enrollment: 590 estimated patients

Sex: All

Ages: 20 to 64 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients diagnosed with major depression based on DSM-IV-TR
• Patients having minimal total score of 18 on the HAM-D17 and minimal score of 2 on the item of "depressed mood" at the baseline.

Exclusion criteria

• Patients with schizophrenia or any other psychotic disorder
• Patients with history or presence of bipolar disorder

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: Double Blind